Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sarikonda, Ghanashyam ^a   Sachithanantham, Sowbarnika ^a   Manenkova, Yulia ^a   Kupfer, Tinalyn ^b   Posgai, Amanda ^c   Wasserfall, Clive ^c   Bernstein, Philip ^d   Straub, Laura ^d   Pagni, Philippe P ^a   Schneider, Darius ^a   Calvo, Teresa Rodriguez ^a   Coulombe, Marilyne ^b   Herold, Kevan ⁱ   Gill, Ronald G ^b   Atkinson, Mark ^c   Nepom, Gerald ^j   Ehlers, Mario ^d   Staeva, Teodora ^e   Garren, Hideki ^f   Steinman, Lawrence ^f,g   Chan, Andrew C ^h   von Herrath, Matthias ^a   more..

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Immune Tolerance Network   (United States)

^e JDRF International   (United States)

^f Bayhill Therapeutics   (United States)

^g STANFORD UNIVERSITY   (United States)

^h GENENTECH INC   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j BENAROYA RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLUCOSE; HUMULIN R U 500; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; PROINSULIN DNA VACCINE; RECOMBINANT HUMAN INSULIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD20 ANTIGEN; INSULIN; MONOCLONAL ANTIBODY; PROINSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD GLUCOSE MONITORING; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG PELLET; HUMORAL IMMUNE DEFICIENCY; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREATIC LYMPH NODE; PROTECTION; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CYTOLOGY; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PANCREAS; PROCEDURES; SPLEEN;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HYPERGLYCEMIA; INSULIN; INTERLEUKIN-4; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PANCREAS; PROINSULIN; SPLEEN; VACCINES, DNA;

EID: 84873666112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054712     Document Type: Article

References (37)

1. Peakman M, von Herrath M, (2010) Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 59: 2087-2093.
2. Gallagher MP, Goland RS, Greenbaum CJ, (2011) Making progress: preserving beta cells in type 1 diabetes. Ann N Y Acad Sci 1243: 119-134.
3. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, et al. (2006) Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116: 1371-1381.
4. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160: 176-184.
5. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, et al. (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet.
6. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, et al. (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076.
7. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, et al. (2011) Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60: 1237-1245.
8. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, et al. (2010) Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34: 408-415.
9. Solvason N, Lou YP, Peters W, Evans E, Martinez J, et al. (2008) Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 181: 8298-8307.
10. Thrower SL, James L, Hall W, Green KM, Arif S, et al. (2009) Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 155: 156-165.
11. von Herrath M, Homann D, (2004) Islet regeneration needed for overcoming autoimmune destruction- considerations on the pathogenesis of type 1 diabetes. Pediatr Diabetes 5Suppl 2: 23-28.
12. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, et al. (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209: 51-60.
13. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, et al. (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220-223.
14. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, et al. (2003) Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 111: 1365-1371.
15. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG, (1999) Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 163: 1833-1838.
16. von Herrath MG, Dyrberg T, Oldstone MB, (1996) Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 98: 1324-1331.
17. Bot A, Smith D, Bot S, Hughes A, Wolfe T, et al. (2001) Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 167: 2950-2955.
18. Coon B, An LL, Whitton JL, von Herrath MG, (1999) DNA immunization to prevent autoimmune diabetes. J Clin Invest 104: 189-194.
19. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698.
20. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, et al. (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.
21. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143-2152.
22. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, et al. (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378: 412-419.
23. Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, et al. (2012) Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 4: 118ra112.
24. Wong FS, Wen L, (2005) B cells in autoimmune diabetes. Rev Diabet Stud 2: 121-135.
25. Hulbert C, Riseili B, Rojas M, Thomas JW, (2001) B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol 167: 5535-5538.
26. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, et al. (2002) The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 32: 3657-3666.
27. Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, et al. (2007) Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 179: 1004-1012.
28. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N, (1998) B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 161: 1163-1168.
29. Noorchashm H, Lieu YK, Noorchashm N, Rostami SY, Greeley SA, et al. (1999) I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 163: 743-750.
30. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, et al. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117: 3857-3867.
31. Serreze DV, Chapman HD, Niens M, Dunn R, Kehry MR, et al. (2011) Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 60: 2914-2921.
32. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, et al. (2008) B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 180: 2863-2875.
33. Yu S, Ellis JS, Dunn R, Kehry MR, Braley-Mullen H (2012) Transient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults. Int Immunol.
34. Fousteri G, Dave A, Bot A, Juntti T, Omid S, et al. (2010) Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 53: 1958-1970.
35. Mauri C, Ehrenstein MR, (2008) The 'short' history of regulatory B cells. Trends Immunol 29: 34-40.
36. http://www.clinicaltrials.gov/ct2/home. Date accessed: September 12th, 2012.
37. Huang H, Benoist C, Mathis D, (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A 107: 4658-4663.